title: Androgen action blockade does not result in reduction in size but changes histology of the normal human prostate.
abstract: The effect of androgen blockade on the normal human prostate was studied in 16 healthy volunteers opting for male-to-female gender reassignment. Their ages ranged from 19 to 27 years. After 8 weeks of treatment with Anandron, serum hormone levels indicated anti-androgenic action and physical signs of feminization appeared. Prostate volumes (measured by ultrasound) before and following Anandron treatment remained the same. After 18 months of treatment with cyproterone-acetate and ethinyl estradiol, prostate volumes again were not changed. However, histology revealed glandular atrophy and an increase in stromal tissue. The significance of these findings is discussed.
mesh_terms: D000328:Adult; D000726:Androgen Antagonists / Q000494:pharmacology*; D003534:Cyproterone / Q000031:analogs & derivatives / Q000494:pharmacology; D017373:Cyproterone Acetate; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D048289:Imidazolidines; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011388:Prolactin / Q000097:blood; D011467:Prostate / Q000033:anatomy & histology* / Q000166:cytology / Q000187:drug effects; D013739:Testosterone / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D007093:Imidazoles; D048289:Imidazolidines; D013739:Testosterone; D004997:Ethinyl Estradiol; D017373:Cyproterone Acetate; C021277:nilutamide; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D003534:Cyproterone